Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
159 hedge funds and large institutions have $1.74B invested in Alder Biopharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 14 closing their positions.
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
39% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 44
29% more capital invested
Capital invested by funds: $1.34B → $1.74B (+$393M)
10% more funds holding
Funds holding: 145 → 159 (+14)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
75% less call options, than puts
Call options by funds: $2.71M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$23M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$21.4M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$12.3M |
| 4 |
SIG
Senator Investment Group
New York
|
+$9.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$57.6M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$17.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.7M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$11.5M |
ALDR Hedge Fund Activity: Q3 2016 in Review
159 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2016, worth a combined $1.74B — up 29% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ALDR positions and 14 closed out — a net gain of 14 holders — while 61 added to existing stakes and 44 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $23M. The largest seller was PFM Health Sciences, cutting an estimated $57.6M.
- 159 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2016, up from 145 in Q2 2016.
- Funds reported $1.74B of Alder Biopharmaceuticals stock for Q3 2016, up 29% quarter-over-quarter.
- 28 funds opened new Alder Biopharmaceuticals positions in Q3 2016 and 14 closed out, a net change of +14 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $23M added.
- The largest Alder Biopharmaceuticals seller in Q3 2016 was PFM Health Sciences, an estimated $57.6M sold.
Based on aggregated 13F filings for Q3 2016.